HKSE
45.86HKD
+0.90 (+2.00%)
We have scored 4 news catalysts on InSilico Medicine Cayman TopCo (3696.HK) over the past 12 months. The biggest single-day move next to one of them came Feb 6, 2026, when 3696.HK closed −8.6%: “Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology”. Coverage across the window leans positive (average ticker sentiment +0.88). Most of the impact sits in forward growth expectations and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Latest scored catalyst for 3696.HK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
26.5B
P/E
—
EPS
—
Beta
2.41
52W range
29.98-80.9
Day range
—
Open
—
Prev close
—
Volume
6.2M
Avg volume
11.3M
Dividend
0.00
IPO
2025-12-30
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about InSilico Medicine Cayman TopCo — not a sector bucket. Click an edge to see the articles that established the link.
